POZEN RECEIVES APPROVAL FOR MT 100 IN THE UNITED KINGDOM

A A

Pozen, Inc., a pharmaceutical company focused primarily on products for the treatment of acute and chronic pain, migraine and other pain-related conditions, announced today the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a Marketing Authorization for MT 100 for the acute treatment of migraine. MT 100 was developed as an oral, first-line treatment for migraine.

Doctor's Guide (http://www.docguide.com/news/content.nsf/news/8525697700573E18852570C70057429E)